


French Translation and Validation of the Synkinesis Assessment Questionnaire

Sarah Martineau , Laurence Gascon, Mikhail Saltychev, Akram Rahal, Karine Marcotte, Sami P. Moubayed

ABSTRACT: Synkinesis is a distressing sequela of peripheral facial palsy (PFP). This study aimed to translate and validate the Synkinesis Assessment Questionnaire (SAQ), a reliable patient-reported outcome evaluation tool for synkinesis, in French. The SAQ was translated following a standard forward–backward translation procedure. After a cognitive debriefing with 10 PFP patients, the SAQ-F was assessed amongst 50 patients for internal consistency, known-group validity, construct validity, criterion validity, and test–retest reliability. Results demonstrated that the SAQ-F was valid, reliable, and had a unidimensional structure. The SAQ-F should be accompanied by clinician-based scales, to provide valuable additional information on the severity of synkinesis.

RÉSUMÉ : Traduction vers le français d'un questionnaire d'évaluation de la syncinésie et validation subséquente. La syncinésie constitue une séquelle éprouvante de la paralysie faciale périphérique (PFP). Cette étude se propose de traduire vers le français le *Synkinesis Assessment Questionnaire* (SAQ), un outil fiable d'évaluation signalée par les patients eux-mêmes, et de valider ensuite ce questionnaire. Ce dernier a été traduit en suivant une procédure standard de traduction avant/arrière (*forward-backward translation procedure*). Après une séance de verbalisation cognitive menée avec 10 patients victimes de PFP, nous avons évalué la cohérence interne, la validité du groupe connu (*known-group validity*), la validité de construit, la validité prédictive et la fidélité test-retest de la version française du SAQ en recourant à un groupe de 50 patients. Nos résultats ont démontré que ce questionnaire traduit était valide et fiable en plus de posséder une structure unidimensionnelle. Il conviendrait aussi de le jumeler à des outils d'évaluation fondés sur la pratique clinique afin de pouvoir fournir des renseignements supplémentaires utiles quant à la gravité des cas de syncinésie.

Keywords: Peripheral facial paralysis, Patient reported outcome measure, Synkinesis, Validation, French

doi:10.1017/cjn.2020.208

Can J Neurol Sci. 2021; 48: 425–429

Facial synkinesis is among the most invalidating consequences of peripheral facial palsy (PFP). It is defined as abnormal muscle contractions of one or many facial areas during volitional facial movement.¹ Synkinesis has numerous functional and cosmetic adverse effects as it limits several day-to-day activities like speaking and eating.² Potential mechanisms for the development of synkinesis could be due to aberrant reinnervation, either by stimulation of neighbor axons in the context of myelin loss or due to hyperexcitability of the facial nucleus.¹

From a research perspective, the use of a validated universal grading system for synkinesis would allow appropriate data pooling and help in establishing valid recommendations for clinical decision-making.³ From a clinical perspective, the evaluation of synkinesis through a patient-reported outcome measure (PROM) is critical to grasp the scope of the handicap that it causes.⁴ Observer-based evaluation of facial function often leads to an incomplete description of patient psychological distress and functional impairments that are caused by the sequelae of facial palsy.⁵

The Synkinesis Assessment Questionnaire (SAQ)² was developed as a specific and validated PROM for synkinesis. While the original English version has demonstrated to be a reliable and valid instrument, there is no existing French equivalent. The purpose of the present study was to create a validated French version of the SAQ in accordance with international guidelines of translation and cultural adaptation.

The present study was approved by the Ethics Review Board of the Centre-intégré-universitaire-de-santé-et-de-services-sociaux du Nord-de-l'Île-de-Montréal (MP-32-2020-1952). Written informed consent was obtained from all participants.

The translation and cultural validation process respected international guidelines.³ A standard forward–backward translation procedure was adopted, with two independent certified translators who produced distinct translations from the original to the target language. Those two translations were merged by the senior researcher of the study. A third translator back-translated the reconciled version for review and identification of discrepancies.

The preliminary version was administered by the first author to 10 native French patients with PFP (women: 8; mean age: 47.4 (15.6)) for cognitive debriefing.³ Appropriate minor changes were then made to the preliminary version and the resulting

From the École d'orthophonie et d'audiologie, Université de Montréal, Montréal, Québec, Canada (SM, KM); Research Center of the Centre intégré universitaire de santé et services sociaux du Nord-de-l'île-de-Montréal, Hôpital du Sacré-Coeur, Montréal, Canada (SM, LG, KM, SPM); Division of Otolaryngology – Head and Neck surgery, Université de Montréal, Montréal, Canada (LG, AR, SPM); and Department of Physical and Rehabilitation Medicine, Turku University Hospital and University of Turku, Turku, Finland (MS)

RECEIVED SEPTEMBER 9, 2020. DATE OF ACCEPTANCE SEPTEMBER 12, 2020.

Correspondence to: Dr Sami-Pierre Moubayed, Facial Plastic and Reconstructive Surgery, Head and Neck Oncology, CIUSSS du Nord-de-l'île de Montréal, 5400 boul. Gouin West, Montreal, Quebec H4J 1C5, Canada. Email: sp.moubayed@gmail.com

SAQ

Veillez répondre aux questions suivantes concernant la fonction faciale du côté du visage atteint par la paralysie faciale, sur une échelle de 1 à 5, selon les classements suivants :

- 1 = rarement ou pas du tout
- 2 = occasionnellement, ou très légèrement
- 3 = parfois, ou légèrement
- 4 = la plupart du temps, ou modérément
- 5 = tout le temps, ou sévèrement

| Question | Score (1 À 5) |
|--|----------------------|
| 1 Lorsque je souris, mon œil se ferme | _____ |
| 2 Lorsque je parle, mon œil se ferme | _____ |
| 3 Lorsque je siffle ou que j'arrondis les lèvres, mon œil ferme | _____ |
| 4 Lorsque je souris, mon cou se tend | _____ |
| 5 lorsque je ferme les yeux, mon visage se contracte | _____ |
| 6 lorsque je ferme les yeux, le coin de ma bouche bouge | _____ |
| 7 lorsque je ferme les yeux, mon cou se tend | _____ |
| 8 Lorsque je mange, mes yeux pleurent | _____ |
| 9 Lorsque je bouge mon visage, des creux apparaissent sur mon menton | _____ |

Figure 1: Synkinesis assessment questionnaire – French.

French version of the SAQ (SAQ-F) was used for validation (Figure 1).

Validation of SAQ-F was conducted with a prospective cohort study including 25 patients with PFP and 25 controls who visited the Otolaryngology clinic for other indications than a PFP (ear infection, dysphonia, tonsillitis, etc.), from February to April 2020. Inclusion criteria were having a PFP and being 18 years old and older. Exclusion criteria were: (1) history of neurological disorders; (2) active psychiatric disease; (3) cognitive disorder; (4) inability to understand written and oral French. For the PFP participants, the severity of facial palsy was assessed using the Facial Nerve Grading System 2.0 (FNGS 2.0; also known as the House-Brackmann 2.0 score)⁶ and the Sunnybrook Facial Grading System (SB).⁷ These were chosen because each has been shown to have high inter-observer agreement and validity.⁸ Specific subscores of synkinesis can be calculated from either scale to allow for more specific analyses. Patients completed the SAQ-F twice within a 2-week interval for test–retest reliability. None of the PFP patients were subject to changes in their treatment.

Of 50 respondents, 25 were PFP patients and 25 controls (Table 1), with 20 men (40%) and 30 women (60%). The average age was 51.6 (18.4) years for the entire sample, 52.7 (18.6) years in PFP and 50.6 (18.4) years in controls. The mean total SAQ score was 18.5 (95% CI 15.7 to 21.2, median 17, range 17–34) points in PFP group, and 9.0 (no variance) points in controls with a difference of –9.5 (95% CI –12.2 to –6.8) points and p -value < 0.0001. Of the PFP patients, 80% were diagnosed with Bell's palsy and the remaining 20% were diagnosed with a PFP

secondary to Ramsay-Hunt's Syndrome, facial nerve schwannoma or traumatic injury. Severity of facial palsy was generally rated as light to moderate with both FNGS 2.0 and SB scales: mean FNGS 2.0 score was 9.4 (4.2) and mean SB score was 73.5 (21.5).

The analyses were performed using Stata/IC Statistical Software: Release 16. College Station (StataCorp LP, TX, USA). The internal consistency of SAQ-F was assessed by using a Chronbach's alpha along with its lower 95% confidence limit (95% CL). Alpha ≥ 0.9 was considered excellent, ≥ 0.8 good, ≥ 0.7 acceptable, ≥ 0.6 questionable, and ≥ 0.5 poor. The known-group validity (PFP vs. controls) was assessed by using a t-test for independent groups in case of total score, and the Kruskal–Wallis nonparametric test for the items' ordinal scores. A two-tailed p -value ≤ 0.05 was considered statistically significant. The test–retest validity of the SAQ-F scale was assessed by employing a Spearman rank correlation coefficient. Exploratory factor analysis (EFA) was used to approximate the construct structure of the SAQ-F and included only PFP patients. The goal was to determine whether the SAQ-F measures only one latent trait (= signs of facial paralysis) or if there are other possible significant latent variables affecting the results. The results were analyzed graphically. After the orthogonal varimax rotation was applied, retained and excluded factors were explored visually on a scree plot along with a parallel analysis. Pearson's product-moment correlation was used when comparing the SAQ-F total score with the synkinesis subscores obtained from the Sunnybrook and FNGS 2.0 scales. Fisher's transformation was used for both Spearman and Pearson's tests. Correlation < 0.2 was

Table 1: Patients demographics

| | Controls | | | | | | PFP patients | | | | | |
|-------------------------|----------|----|------|------|--------|-------|--------------|----|------|------|--------|-------|
| | n | % | Mean | SD | Median | Range | n | % | Mean | SD | Median | Range |
| Gender | | | | | | | | | | | | |
| Male | 11 | 44 | | | | | 9 | 36 | | | | |
| Female | 14 | 56 | | | | | 16 | 64 | | | | |
| Age (years) | | | 50.6 | 18.4 | 56 | 23–90 | | | 52.7 | 18.6 | 53 | 19–95 |
| Diagnosis | | | | | | | | | | | | |
| Bells | | | | | | | 20 | 80 | | | | |
| Ramsay Hunt | | | | | | | 2 | 8 | | | | |
| Facial nerve Schwannoma | | | | | | | 2 | 8 | | | | |
| Traumatic injury | | | | | | | 1 | 4 | | | | |
| Side | | | | | | | | | | | | |
| Left | | | | | | | 11 | 44 | | | | |
| Right | | | | | | | 14 | 56 | | | | |
| FNGS 2.0 total score | | | | | | | | | 9.44 | 4.2 | 9 | 9–24 |
| Sunnybrook total score | | | | | | | | | 73.5 | 21.5 | 76 | 5–97 |
| SAQ-F total score | | | 9 | 0 | 9 | 9 | | | 18.5 | 17 | 17 | 34 |

Note: PFP= peripheral facial palsy; n = number; SD = standard deviation; Facial Nerve Grading Scale 2.0 (FNGS 2.0) scores: 24 = total palsy; 4 = no facial palsy. Sunnybrook (SB) scores: minimum possible = 0 or total palsy; maximum possible = 100% or normal; SAQ scores: 9 = no synkinesis; 45 = severe synkinesis.

Table 2: Test–retest validity of the SAQ-F (including both PFP and control groups)

| | <i>r</i> | 95% CI Lower limit vs. upper limit | |
|-------------|----------|------------------------------------|------|
| Total score | 0.96 | 0.93 | 0.98 |
| Item 1 | 0.78 | 0.65 | 0.87 |
| Item 2 | 0.92 | 0.87 | 0.96 |
| Item 3 | 0.93 | 0.88 | 0.96 |
| Item 4 | 0.92 | 0.85 | 0.95 |
| Item 5 | 0.69 | 0.51 | 0.81 |
| Item 6 | 0.90 | 0.82 | 0.94 |
| Item 7 | 0.60 | 0.38 | 0.75 |
| Item 8 | 0.89 | 0.81 | 0.94 |
| Item 9 | 0.81 | 0.69 | 0.89 |

Note: SAQ-F = Synkinesis Assessment Questionnaire – French; PFP = peripheral facial palsy; CI = confidence interval.

considered poor, from 0.21 to 0.4 fair, from 0.41 to 0.6 moderate, from 0.61 to 0.8 substantial, and >0.8 perfect.

Results showed that the internal consistency of the SAQ-F was good with alpha of 0.87 (lower 95% CL 0.82). Results of the test–retest reliability were substantial to perfect for the total score as well as for all nine items individually (0.96, 95% CI 0.93 to 0.98) (Table 2). Known-group validity of SAQ-F appeared to be high as there were significant differences between groups in the total score and in seven out of nine items' scores ($p < 0.01$) (Table 3). Construct validity of the SAQ-F was tested by an

Table 3: Know-group validity – differences in SAQ-F scores between PFP and control groups


| | <i>p</i> -value |
|-------------|----------------------|
| Total score | <0.0001 ^a |
| Item 1 | 0.0002 ^b |
| Item 2 | 0.0015 ^b |
| Item 3 | 0.0006 ^b |
| Item 4 | 0.0033 ^b |
| Item 5 | 0.0015 ^b |
| Item 6 | 0.0001 ^b |
| Item 7 | 0.0500 ^b |
| Item 8 | 0.0041 ^b |
| Item 9 | 0.2207 ^b |

Note: ^aIndependent groups *t*-test; ^bKruskal–Wallis test; SAQ-F = Synkinesis Assessment Questionnaire – French; PFP = peripheral facial palsy; CI = confidence interval.

exploratory factor analysis (Table 4 and Figure 2). The parallel analysis of the scree plot showed that SAQ-F had three factors with positive Eigen values above the parallel analysis line. However, the Eigen values of the second and third factors were as low as 1.2 and 0.6 respectively and were disregarded for retaining. Thus, the SAQ-F was considered to have a unidimensional structure with one factor, whose Eigen value was 3.1. When assessing the criterion validity based on the 25 PFP patients, Pearson's product–moment correlation of the SAQ-F total score and the FNGS 2.0 synkinesis subscore was not significant

Table 4: Rotated factor loadings (pattern matrix) and unique variances

| Variable | Factors | | | | | Uniqueness |
|----------|---------|-------|-------|-------|-------|------------|
| | 1 | 2 | 3 | 4 | 5 | |
| Item 1 | 0.10 | 0.28 | 0.70 | 0.02 | 0.00 | 0.42 |
| Item 2 | 0.10 | 0.87 | 0.21 | -0.10 | -0.09 | 0.16 |
| Item 3 | 0.19 | 0.88 | 0.01 | 0.08 | 0.12 | 0.17 |
| Item 4 | 0.68 | 0.12 | 0.44 | 0.13 | 0.08 | 0.30 |
| Item 5 | 0.74 | 0.33 | 0.09 | -0.04 | 0.08 | 0.33 |
| Item 6 | 0.54 | 0.40 | 0.13 | 0.01 | 0.28 | 0.45 |
| Item 7 | 0.84 | 0.05 | -0.05 | 0.01 | -0.07 | 0.28 |
| Item 8 | 0.03 | -0.15 | 0.05 | -0.34 | -0.01 | 0.86 |
| Item 9 | 0.13 | -0.18 | 0.19 | 0.44 | 0.01 | 0.72 |

**Figure 2:** Scree plot of the factor analysis along with parallel analysis of the SAQ-F for construct validity.

($r = -0.23$; 95% CI: -0.57 to 0.18). The Spearman's rank correlation of SAQ-F total score with Sunnybrook synkinesis subscore was also not significant ($r = -0.19$; 95% CI: -0.55 to 0.22).

In this study, we presented the translation and validation of the SAQ-F, a French patient-centered questionnaire based on the original English SAQ.² The SAQ scale allows to quantify the patient's perception of synkinesis' severity and thus allows to adapt the management and overall care of synkinesis, to fit the patient's expectations. Cross-cultural adaptation and validation is necessary in the use of PROM questionnaires, to avoid misinterpretation while using questionnaires developed in other countries.³ To our knowledge, no other study validated the SAQ scale in French. Thus, the SAQ-F will be highly relevant for many clinical and research settings in Quebec and other French-speaking regions.

We translated and validated the SAQ-F according to the best practice's international guidelines.³ Our results showed that the SAQ-F has good internal consistency, a high test-retest reliability, a high known-group validity, allowing to distinguish between controls and PFP patients, as well as good construct validity. Compared to the original version, the SAQ-F presented a slightly higher internal consistency (0.87 for SAQ-F and 0.80 for

SAQ) and test-retest reliability (0.96 in our study and 0.881 in the original one).

Correlations with synkinesis subscores of clinician-based questionnaires were not significant. Other studies already reported discrepancies between PROM and clinician-based physical examination.⁵ A high correlation between both measures is probably not to be expected, and both of them should be taken for a complete overview of the synkinesis severity.^{1,2}

This study is not without limitation. As the data comes from a small number of patients, nonsignificant results regarding criterion validity could be due to lack of power. Due to practical reasons, the group size was limited to 25 patients, which is nonetheless comparable with many other PROM studies in the literature about PFP.⁹ Further research may reveal valuable information about SAQ-F psychometric properties by employing, for example, item response theory analysis (IRT).¹⁰

The SAQ-F was found to be a reliable, easy-to-use, and valid unidimensional scale to assess synkinesis after PFP. The SAQ-F should be accompanied by clinician-based scales to provide valuable additional information on the severity of synkinesis.

ACKNOWLEDGEMENTS

The authors would like to thank Anne-Marie Chouinard for her contribution in the development of the research protocol.

DISCLOSURE

None.

STATEMENT OF AUTHORSHIP

SM and LG participated in the development of the research protocol, recruitment of patients and the redaction of the article. AR and KM participated in the redaction of the article. MS participated in the analysis of data and redaction of the article. SPM supervised each step of the research.

REFERENCES

1. Kleiss JJ, Beurskens CHG, Stalmeier PFM, Ingels KJAO, Marres HAM. Synkinesis assessment in facial palsy: validation of the Dutch synkinesis assessment questionnaire. *Acta Neurol Belg.* 2016;116(2):171-78.

2. Mehta RP, WernickRobinson M, Hadlock TA. Validation of the synkinesis assessment questionnaire. *Laryngoscope* 2007;117(5): 923–6.
3. Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. *Value Health* 2005;8(2): 94–104.
4. VanSwearingen JM, Cohn JF, Turnbull J, Mrzai T, Johnson P. Psychological distress: Linking impairment with disability in facial neuromotor disorders. *Otolaryngol Head Neck Surg.* 1998;118(6):790–6.
5. Marsk E, Hammarstedt-Nordenvall L, Engstrom M, Jonsson L, Hultcrantz M. Validation of a swedish version of the Facial Disability Index (FDI) and the Facial Clinimetric Evaluation (FaCE) scale. *Acta Otolaryngol.* 2013;133:662–9.
6. Vrabec JT, Backous DD, Djalilian HR, et al. Facial nerve grading system 2.0. *Otolaryngol Head Neck Surg.* 2009;140:445–50.
7. Ross B, Fradet G, Nedzelski JM. Development of a sensitive clinical facial grading system. *Otolaryngol Head Neck Surg.* 1996;114: 380–6.
8. Fattah AY, Gurusinghe AD, Gavilan J, et al. Facial nerve grading instruments: Systematic review of the literature and suggestion for uniformity. *Plastic Reconstructive Surg.* 2015;135: 569–79.
9. Luijmes RE, Pouwels S, Beurskens CH, Kleiss JJ, Siemann I, Ingels KJ. Quality of life before and after different treatment modalities in peripheral facial palsy: a systematic review. *Laryngoscope.* 2017;127(5):1044–51.
10. Nguyen TH, Han HR, Kim MT, Chan KS. An introduction to item response theory for patient-reported outcome measurement. *Patient.* 2014;7(1):23–35.